近日,博纳西亚(杭州)医药科技股份有限公司(简称:博纳西亚)向港交所主板递交上市申请,兴证国际、工银国际为其联席保荐人。招股书显示,这家总部位于杭州的临床合同研究组织(CRO)致力于通过数字化赋能创新药临床研究,深耕肿瘤及自身免疫性疾病两大领域,于2024年已取得约6729.1万元盈利。不过,与此同时,公司现金流、应收账款状况面临考验,且公司市场份额并不占优,或将成为市场投资者担忧的因素。在巨头...
Source Link近日,博纳西亚(杭州)医药科技股份有限公司(简称:博纳西亚)向港交所主板递交上市申请,兴证国际、工银国际为其联席保荐人。招股书显示,这家总部位于杭州的临床合同研究组织(CRO)致力于通过数字化赋能创新药临床研究,深耕肿瘤及自身免疫性疾病两大领域,于2024年已取得约6729.1万元盈利。不过,与此同时,公司现金流、应收账款状况面临考验,且公司市场份额并不占优,或将成为市场投资者担忧的因素。在巨头...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.